Check out our recent news
oct 2021
Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board
oct 2021
Delix Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2021
sept 2021
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
aug 2021
Delix Therapeutics Continues Rapid Growth with Appointment of Chief Medical Officer
july 2021
Delix Therapeutics Expands Executive Leadership Team
june 2021
Delix Therapeutics Announces Scientific and Strategic Advisory Board Appointments
may 2021
Delix Therapeutics Retains KSCA Strategic Communications
apr 2021
Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog -- Without Hallucinogenic Effects
mar 2021